Video Series

Drs Lebwohl and Groves list support services to help with patient adherence.

Bhavesh Shah, PharmD, explains how lower volume agents can be beneficial when treating plaque psoriasis and metabolic syndrome.

Robert Groves, MD, and Bhavesh Shah, PharmD, comment on the role real-world evidence plays in creating cost/value analyses for psoriasis and metabolic syndrome.

Dr Groves discusses the impact of population health knowledge in patients with metabolic syndrome.

Dr Lebwohl explains how he can recognize who will respond early to psoriasis treatments and who won’t respond at all.

Bhavesh Shah, PharmD, elaborates on switching biologics in psoriasis treatment.

Drs Lebwohl and Groves comment on what they factor in when deciding to switch agents and provide targeted treatments for psoriasis and metabolic syndrome.

Ryan Haumschild, PharmD, MS, MBA discusses the potential to lower total costs through care pathways designed to start patients with plaque psoriasis and metabolic syndrome on treatments that have shown to have better overall outcomes, such as tildrakizumab.

Jason Starr, DO, explains circulating tumor DNA’s (ctDNA) role in oncology and its role in MRD.

Mark Lebwohl, MD, details how he extrapolates clinical data in his decision-making when trying to treat patients with psoriasis.

Drs Groves and Lebwohl discuss payer considerations for ensuring treatment with the appropriate agent for patients with psoriasis and metabolic syndrome.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, elaborate on treatment effectiveness in patients with both psoriasis and metabolic syndrome.

Drs Lebwohl and Groves discuss patients with psoriasis and the increased risk they have for also being diagnosed with metabolic syndrome.

Bhavesh Shah, PharmD, and Mark Lebwohl, MD, explain the difficulties of patient adherence to psoriasis treatments.

Dr Mark Lebwohl explains disease burden for patients with plaque psoriasis and discusses the common comorbidities clinicians see.

Kathy Oubre, MS, closes this Insights program by evaluating her organization’s biosimilars program and formularies, including third party preference on the use of specific biosimilars and whether biosimilars can be used outside of their indications.

Two experts explain if they had to create any incentives for health care providers to prescribe biosimilars, whether they encountered challenges with their electronic health records, and if their biosimilar programs impacted their clinical pathway/care plans.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss tracking their use of biosimilar by their providers and outcome measures they utilize to monitor biosimilars.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, recall what protocols and laws their organizations needed to abide by when transitioning to their biosimilars programs.

Two experts examine how the biosimilar programs at their organization were created and the initial goals they had in mind.

Ryan Haumschild, PharmD, MS, MBA, and Kathy Oubre, MS, discuss the increased use of biosimilars, including successes and challenges and the process of transitioning to biosimilars at their organizations.

Ryan Haumschild, PharmD, MS, MBA, discusses optimizing the transition to biosimilars, covering from what patients to look for as candidates to the process of switching a patient from a brand to a biosimilar to the importance of patient education.

Ryan Haumschild, PharmD, MS, MBA, continues focusing on transition optimization, explaining how to efficiently create your inventory, how his use of biosimilars will change in the future, and offering advice to those looking to transition to biosimilars.